TherapeuticsMD (NASDAQ:TXMD) had its price target cut by Cowen from $16.00 to $9.00 in a research note issued on Tuesday, The Fly reports. The firm presently has an “outperform” rating on the stock. Cowen’s price target suggests a potential upside of 254.33% from the company’s current price.

Several other equities analysts have also recently issued reports on TXMD. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, April 27th. Cantor Fitzgerald reaffirmed a “positive” rating on shares of TherapeuticsMD in a report on Thursday, April 18th. BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. ValuEngine lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, JPMorgan Chase & Co. cut their price objective on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. TherapeuticsMD currently has an average rating of “Hold” and an average price target of $11.16.

TXMD stock traded up $0.16 during mid-day trading on Tuesday, hitting $2.54. 84,953 shares of the stock were exchanged, compared to its average volume of 3,187,358. The firm has a market cap of $759.85 million, a P/E ratio of -4.37 and a beta of 2.14. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26. TherapeuticsMD has a 12 month low of $2.21 and a 12 month high of $7.42.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The company had revenue of $3.95 million for the quarter, compared to the consensus estimate of $5.96 million. During the same quarter in the previous year, the business earned ($0.11) EPS. TherapeuticsMD’s revenue was up 4.8% compared to the same quarter last year. As a group, research analysts expect that TherapeuticsMD will post -0.64 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of TXMD. FMR LLC grew its position in shares of TherapeuticsMD by 50.1% in the 4th quarter. FMR LLC now owns 18,088,341 shares of the company’s stock valued at $68,917,000 after buying an additional 6,038,353 shares during the last quarter. Frontier Capital Management Co. LLC lifted its stake in shares of TherapeuticsMD by 291.5% in the first quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after purchasing an additional 4,360,963 shares during the period. Rubric Capital Management LP lifted its stake in shares of TherapeuticsMD by 203.6% in the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock valued at $22,845,000 after purchasing an additional 3,145,742 shares during the period. Millennium Management LLC increased its holdings in TherapeuticsMD by 590.6% during the 4th quarter. Millennium Management LLC now owns 2,848,750 shares of the company’s stock valued at $10,854,000 after acquiring an additional 2,436,259 shares in the last quarter. Finally, Daruma Capital Management LLC increased its holdings in TherapeuticsMD by 11.8% during the 1st quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock valued at $34,631,000 after acquiring an additional 750,235 shares in the last quarter. 78.93% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: Does a trade war provide a risk to the global economy?

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.